+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
MALE
ID06783127

Observing Clinical Outcomes of Olaparib Treatment in Men with BRCA Mutant Castration Resistant Prostate Cancer

Led by Santa Chiara Hospital · Updated on 2025-02-11

3000

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This observational study focuses on men with metastatic castration-resistant prostate cancer mCRPC who have a BRCA mutation. Researchers aim to understand overall survival, clinical outcomes, and factors that may predict or influence these results for patients treated with olaparib in real-world clinical settings. The study is designed to gather both retrospective and prospective data from multiple centers. Participants in this study are mCRPC patients receiving olaparib as part of their routine clinical care. Olaparib is given according to standard practice for BRCA-positive patients. There is no placebo or comparison group, as this study observes outcomes from patients on olaparib in everyday use. During the study, researchers will collect information about disease control from treatment start until the last follow-up or death, up to 120 months. They will also monitor biochemical responses, response rates, progression-free survival, and toxicity over an average of one year. This helps to provide a comprehensive picture of how patients respond to olaparib in typical clinical practice.

CONDITIONS

Brief Title

Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer

Research Team

O

Orazio Caffo, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here